相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
Mohamed A. Ghonim et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
Jinyu Meng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
Marilyne Labrie et al.
NPJ PRECISION ONCOLOGY (2021)
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Marine Bruand et al.
CELL REPORTS (2021)
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita K. Mehta et al.
NATURE CANCER (2021)
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice
Lucia Moreno-Lama et al.
ONCOGENE (2020)
A multi-batch design to deliver robust estimates of efficacy and reduce animal use - a syngeneic tumour case study
Natasha A. Karp et al.
SCIENTIFIC REPORTS (2020)
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd et al.
ONCOGENE (2020)
Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy
Mayassa J. Bou-Dargham et al.
BMC CANCER (2020)
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
Alejandra Martinez et al.
CANCERS (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Timo Reislander et al.
MOLECULAR CELL (2020)
Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity
Jacqueline A. Carozza et al.
NATURE CANCER (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Roman M. Chabanon et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Zebin Wang et al.
SCIENTIFIC REPORTS (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Timo Reislander et al.
NATURE COMMUNICATIONS (2019)
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Daehwan Kim et al.
NATURE BIOTECHNOLOGY (2019)
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
Ik Sun Kim et al.
NATURE CELL BIOLOGY (2019)
1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
S Domchek et al.
ANNALS OF ONCOLOGY (2019)
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
Molly A. Taylor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
Anne Margriet Heijink et al.
NATURE COMMUNICATIONS (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
The Tumor Immune Contexture of Prostate Cancer
Natasha Vitkin et al.
FRONTIERS IN IMMUNOLOGY (2019)
Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
Julie M. Diamond et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
Gillian Dunphy et al.
MOLECULAR CELL (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
Meng Michelle Xu et al.
IMMUNITY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3
Moritz M. Gaidt et al.
CELL (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Tianli Xia et al.
CANCER RESEARCH (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis
Tianli Xia et al.
CELL REPORTS (2016)
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
Jing Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity
Anetta Hartlova et al.
IMMUNITY (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells
Jared Klarquist et al.
JOURNAL OF IMMUNOLOGY (2014)
Growth Rate Analysis and Efficient Experimental Design for Tumor Xenograft Studies
Gregory Hather et al.
CANCER INFORMATICS (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
STING Recognition of Cytoplasmic DNA Instigates Cellular Defense
Takayuki Abe et al.
MOLECULAR CELL (2013)
Type I interferon response and innate immune sensing of cancer
Mercedes B. Fuertes et al.
TRENDS IN IMMUNOLOGY (2013)
Qualimap: evaluating next-generation sequencing alignment data
Fernando Garcia-Alcalde et al.
BIOINFORMATICS (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Carol Kilkenny et al.
PLOS BIOLOGY (2010)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Regulation of transcription factor NFAT by ADP-ribosylation
Opeyemi A. Olabisi et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Regulation of NFAT by poly (ADP-ribose) polymerase activity in T cells
Rut Valdor et al.
MOLECULAR IMMUNOLOGY (2008)
IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes
Pamela I. Osterlund et al.
JOURNAL OF IMMUNOLOGY (2007)
A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma
Deyin Xing et al.
CANCER RESEARCH (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
